Loading...

We've got a brand new version of Simply Wall St! Try it out

Sunmax Biotechnology

GTSM:4728
Snowflake Description

Excellent balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4728
GTSM
NT$4B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Sunmax Biotechnology Co., Ltd., a biomedical company, produces and sells medical-grade collagen medical devices in Asia. The last earnings update was 89 days ago. More info.


Add to Portfolio Compare Print
  • Sunmax Biotechnology has significant price volatility in the past 3 months.
4728 Share Price and Events
7 Day Returns
-7.8%
GTSM:4728
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
135.7%
GTSM:4728
-9.6%
TW Biotechs
17.7%
TW Market
4728 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sunmax Biotechnology (4728) -7.8% -14.9% -0.6% 135.7% 100.5% 217.6%
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 4728 outperformed the Biotechs industry which returned -9.6% over the past year.
  • 4728 outperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4728
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Sunmax Biotechnology's competitors could be found in our database.

4728 Value

 Is Sunmax Biotechnology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sunmax Biotechnology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sunmax Biotechnology.

GTSM:4728 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 9.9%
Perpetual Growth Rate 10-Year TW Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for GTSM:4728
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year TW Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.278 (1 + (1- 20%) (2.78%))
1.206
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.21
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.206 * 5.96%)
9.91%

Discounted Cash Flow Calculation for GTSM:4728 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sunmax Biotechnology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

GTSM:4728 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (TWD, Millions) Source Present Value
Discounted (@ 9.91%)
2020 284.42 Est @ 56.98% 258.77
2021 400.19 Est @ 40.7% 331.25
2022 517.49 Est @ 29.31% 389.70
2023 627.90 Est @ 21.34% 430.20
2024 726.83 Est @ 15.75% 453.05
2025 812.93 Est @ 11.85% 461.02
2026 887.01 Est @ 9.11% 457.65
2027 950.85 Est @ 7.2% 446.33
2028 1,006.54 Est @ 5.86% 429.86
2029 1,056.05 Est @ 4.92% 410.32
Present value of next 10 years cash flows NT$4,068.00
GTSM:4728 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= NT$1,056.05 × (1 + 2.73%) ÷ (9.91% – 2.73%)
NT$15,099.48
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NT$15,099.48 ÷ (1 + 9.91%)10
NT$5,866.73
GTSM:4728 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NT$4,068.00 + NT$5,866.73
NT$9,934.73
Equity Value per Share
(TWD)
= Total value / Shares Outstanding
= NT$9,934.73 / 54.46
NT$182.41
GTSM:4728 Discount to Share Price
Calculation Result
Value per share (TWD) From above. NT$182.41
Current discount Discount to share price of NT$81.30
= -1 x (NT$81.30 - NT$182.41) / NT$182.41
55.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Sunmax Biotechnology is available for.
Intrinsic value
>50%
Share price is NT$81.3 vs Future cash flow value of NT$182.41
Current Discount Checks
For Sunmax Biotechnology to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Sunmax Biotechnology's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Sunmax Biotechnology's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sunmax Biotechnology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sunmax Biotechnology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4728 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$1.83
GTSM:4728 Share Price ** GTSM (2019-11-11) in TWD NT$81.3
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sunmax Biotechnology.

GTSM:4728 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4728 Share Price ÷ EPS (both in TWD)

= 81.3 ÷ 1.83

44.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunmax Biotechnology is overvalued based on earnings compared to the TW Biotechs industry average.
  • Sunmax Biotechnology is overvalued based on earnings compared to the Taiwan, Province of China market.
Price based on expected Growth
Does Sunmax Biotechnology's expected growth come at a high price?
Raw Data
GTSM:4728 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 44.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
-14%per year
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sunmax Biotechnology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sunmax Biotechnology's assets?
Raw Data
GTSM:4728 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$11.71
GTSM:4728 Share Price * GTSM (2019-11-11) in TWD NT$81.3
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:4728 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4728 Share Price ÷ Book Value per Share (both in TWD)

= 81.3 ÷ 11.71

6.94x

* Primary Listing of Sunmax Biotechnology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunmax Biotechnology is overvalued based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess Sunmax Biotechnology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sunmax Biotechnology has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4728 Future Performance

 How is Sunmax Biotechnology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Sunmax Biotechnology, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-14%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sunmax Biotechnology expected to grow at an attractive rate?
  • Sunmax Biotechnology's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Sunmax Biotechnology's earnings are expected to decrease over the next 1-3 years, this is below the Taiwan, Province of China market average.
  • Unable to compare Sunmax Biotechnology's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4728 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:4728 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts -14%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4728 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4728 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 427 190 99
2019-03-31 347 133 82
2018-12-31 304 101 75
2018-09-30 259 73 50
2018-06-30 229 76 40
2018-03-31 200 58 28
2017-12-31 190 37 17
2017-09-30 189 45 24
2017-06-30 188 34 24
2017-03-31 164 -4 2
2016-12-31 156 17 2
2016-09-30 120 -19 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sunmax Biotechnology's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Unable to determine if Sunmax Biotechnology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4728 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sunmax Biotechnology Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4728 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 1.83
2019-03-31 1.51
2018-12-31 1.38
2018-09-30 0.92
2018-06-30 0.74
2018-03-31 0.53
2017-12-31 0.31
2017-09-30 0.45
2017-06-30 0.44
2017-03-31 0.03
2016-12-31 0.03
2016-09-30 -0.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sunmax Biotechnology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sunmax Biotechnology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sunmax Biotechnology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4728 Past Performance

  How has Sunmax Biotechnology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sunmax Biotechnology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sunmax Biotechnology has delivered over 20% year on year earnings growth in the past 5 years.
  • Sunmax Biotechnology's 1-year earnings growth exceeds its 5-year average (148.6% vs 46.1%)
  • Sunmax Biotechnology's earnings growth has exceeded the TW Biotechs industry average in the past year (148.6% vs -7.5%).
Earnings and Revenue History
Sunmax Biotechnology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sunmax Biotechnology Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4728 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 426.96 99.47 227.67 23.04
2019-03-31 346.56 82.01 184.08 23.73
2018-12-31 304.07 74.66 158.01 19.51
2018-09-30 258.75 49.64 140.31 16.42
2018-06-30 229.13 40.01 130.55 15.86
2018-03-31 200.00 28.47 123.41 12.11
2017-12-31 190.13 16.54 112.48 11.83
2017-09-30 189.07 24.00 100.12 13.92
2017-06-30 187.56 23.90 86.70 13.07
2017-03-31 163.88 1.86 76.91 17.17
2016-12-31 155.53 1.74 76.50 19.54
2016-09-30 120.09 -31.49 81.14 19.14
2016-06-30 111.98 -44.75 89.03 22.17
2016-03-31 114.40 -39.82 93.91 20.11
2015-12-31 111.65 -44.16 94.47 21.48
2015-09-30 151.14 -17.13 92.99 30.36
2015-06-30 150.81 0.47 85.51 28.15
2015-03-31 164.94 13.07 79.07 25.73
2014-12-31 183.88 20.24 78.21 21.58
2014-09-30 176.52 25.44 76.90 9.85
2014-06-30 192.85 27.56 79.30 9.23
2014-03-31 212.39 40.87 80.62 9.25
2013-12-31 213.36 48.14 81.81 10.76
2013-09-30 226.80 50.71 82.23 13.61
2013-06-30 189.07 35.76 76.48 13.78
2013-03-31 152.69 20.02 69.14 15.82
2012-12-31 139.20 16.26 64.88 16.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Sunmax Biotechnology has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Sunmax Biotechnology used its assets more efficiently than the TW Biotechs industry average last year based on Return on Assets.
  • Sunmax Biotechnology has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Sunmax Biotechnology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sunmax Biotechnology has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4728 Health

 How is Sunmax Biotechnology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sunmax Biotechnology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sunmax Biotechnology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sunmax Biotechnology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sunmax Biotechnology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.177908118453E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sunmax Biotechnology Company Filings, last reported 4 months ago.

GTSM:4728 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 637.65 0.00 660.15
2019-03-31 676.17 0.00 575.30
2018-12-31 648.01 24.00 526.29
2018-09-30 615.87 24.00 483.89
2018-06-30 606.39 24.00 496.45
2018-03-31 591.13 24.00 458.38
2017-12-31 572.70 24.00 445.59
2017-09-30 566.96 0.00 470.06
2017-06-30 561.04 0.00 451.58
2017-03-31 553.72 0.00 432.47
2016-12-31 555.29 0.00 447.72
2016-09-30 543.80 0.00 433.76
2016-06-30 541.92 0.00 428.05
2016-03-31 561.38 0.00 453.06
2015-12-31 558.24 0.00 443.32
2015-09-30 582.12 0.00 445.46
2015-06-30 599.78 0.00 487.34
2015-03-31 657.37 0.00 510.80
2014-12-31 659.31 0.00 508.79
2014-09-30 651.31 0.00 489.54
2014-06-30 642.09 0.00 504.43
2014-03-31 676.33 0.00 509.39
2013-12-31 669.86 0.00 515.18
2013-09-30 657.50 0.00 502.00
2013-06-30 647.69 0.00 529.97
2013-03-31 659.42 0.00 490.99
2012-12-31 645.72 0.00 492.30
  • Sunmax Biotechnology's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Sunmax Biotechnology's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (1.3382235186499E+18%, greater than 20% of total debt).
  • Sunmax Biotechnology earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess Sunmax Biotechnology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sunmax Biotechnology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4728 Dividends

 What is Sunmax Biotechnology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.48%
Current annual income from Sunmax Biotechnology dividends.
If you bought NT$2,000 of Sunmax Biotechnology shares you are expected to receive NT$30 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Sunmax Biotechnology's pays a lower dividend yield than the bottom 25% of dividend payers in Taiwan, Province of China (2.59%).
  • Sunmax Biotechnology's dividend is below the markets top 25% of dividend payers in Taiwan, Province of China (5.95%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4728 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:4728 Past Annualized Dividends Data
Date (Data in NT$) Dividend per share (annual) Avg. Yield (%)
2019-05-15 1.200 1.443
2019-03-25 1.200 1.791
2019-03-21 1.200 1.931
2018-03-31 0.300 0.796
2018-03-29 0.300 0.861
2017-03-20 0.000 0.000
2016-11-10 0.000 0.000
2016-10-17 0.000 0.000
2016-08-12 0.000 0.000
2016-08-11 0.000 0.000
2016-05-12 0.000 0.000
2016-05-10 0.000 0.000
2016-03-31 0.000 0.000
2015-03-30 0.600 2.120
2014-05-02 0.600 2.018
2013-03-28 0.500 1.313
2012-09-10 0.600 1.901
2012-03-30 0.600 1.914

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunmax Biotechnology has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Dividend payments have increased, but Sunmax Biotechnology only paid a dividend in the past 8 years.
Current Payout to shareholders
What portion of Sunmax Biotechnology's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.5x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sunmax Biotechnology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sunmax Biotechnology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sunmax Biotechnology has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4728 Management

 What is the CEO of Sunmax Biotechnology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Sunmax Biotechnology has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Sunmax Biotechnology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sunmax Biotechnology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4728 News

Simply Wall St News

4728 Company Info

Description

Sunmax Biotechnology Co., Ltd., a biomedical company, produces and sells medical-grade collagen medical devices in Asia. The company offers Porcogen, a sterile solution of purified collagen for tissue engineering and medical research activities; and dermal fillers, such as Sunmax collagen implant I-Plus and Sumax collagen implant I for the correction of facial defects, such as the fill up of wrinkles. It also provides Sunmax collagen dental membrane and Sunmax collagen bone graft, which are used in the augmentation or reconstructive treatment of the alveolar ridge; and Sunmax dental bone graft granules. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; PEZRI collagen activated repairing products; and skincare products comprising Sunmax 6 collagen facial cleanser, Sunmax 7 collagen essence, Sunmax 8 active collagen essence mask, Sunmax 9 collagen refining cream, Sunmax 10 collagen eye renewal cream, and Sunmax 11 collagen moisturizing cream that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is based in Tainan City, Taiwan.

Details
Name: Sunmax Biotechnology Co., Ltd.
4728
Exchange: GTSM
Founded: 2001
NT$4,427,841,900
54,463,000
Website: http://www.sunmaxbiotech.com
Address: Sunmax Biotechnology Co., Ltd.
No.10, Lane. 31,
2nd Floor,
Tainan City,
744,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4728 Common Stock Taipei Exchange TW TWD 25. Jan 2010
Number of employees
Current staff
Staff numbers
0
Sunmax Biotechnology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 14:57
End of day share price update: 2019/11/11 00:00
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.